Pegfilgrastim

Ocrelizumab is an anti-CD20 mAb and the only approved disease-modifying therapy for primary progressive multiple sclerosis (PPMS). With semiannual infusion and nearly 50% reduction in annualized relapse rate for RMS, it holds an unmatched position in neuroimmunology.

Octreotide Scetate is a long-acting release formulation of octreotide acetate encapsulated in biodegradable PLGA microspheres, providing sustained release for approximately 28 days following intramuscular injection. It dramatically improves patient adherence and quality of life compared to multiple daily s...

Ofatumumab is an anti-CD20 mAb; it is used for CLL and relapsing multiple sclerosis. Its monthly subcutaneous self-injection enables thorough B-cell depletion with significantly superior compliance vs intravenous CD20 alternatives.

Paclitaxel is a Cremophor-free, albumin-bound paclitaxel formulation where paclitaxel is delivered in a suspension of albumin nanoparticles. It is administered as a 30-minute IV infusion without steroid or antihistamine premedication. It eliminates the need for Cremophor EL solvent, thereby removing the ri...

Paliperidone Palmitate is a long-acting injectable (LAI) formulation using nanocrystal technology. It is supplied as prefilled syringes requiring no refrigeration or reconstitution, offering once-monthly (1M) and three-monthly (3M) dosing options for schizophrenia, which significantly improves treatment ad...

Panitumumab is a fully human anti-EGFR mAb for RAS wild-type metastatic colorectal cancer. Its fully human sequence minimizes immunogenicity, with proven survival benefit in FOLFOX combination, representing a key precision therapy option in CRC.

Pembrolizumab is an anti-PD-1 mAb with the broadest approved indication portfolio globally. Spanning NSCLC first-line to MSI-H/TMB-H pan-tumor indications, it represents the absolute benchmark in immuno-oncology with an exceptionally high market ceiling.

Pertuzumab is an anti-HER2 mAb blocking HER2 dimerization with other HER family receptors. As a core component of dual-target therapy with trastuzumab in HER2+ breast cancer, it holds a firmly established position in high-value oncology segments.

Pertuzumab, trastuzumab, and hyaluronidase is a subcutaneous fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase. Replacing hours of IV infusion with 15-minute subcutaneous administration, it revolutionizes outpatient convenience and marks a milestone in breast cancer treatment delivery.

Ranibizumab is an anti-VEGF-A Fab fragment for wet AMD and DME. As the gold standard in ophthalmic anti-VEGF therapy, it established the foundation of the retinal disease drug market, with clear biosimilar substitution potential post-patent expiry.

Risankizumab is an anti-IL-23 p19 mAb for psoriasis, Crohn's disease, and ulcerative colitis. With industry-leading PASI 90 response rates and q12w maintenance dosing, it offers exceptional compliance and ranks among the fastest-growing assets in immunology.

Romiplostim is a TPO receptor agonist peptibody for immune thrombocytopenia (ITP). As the standard second-line therapy with long-acting subcutaneous design, it remains effective in splenectomy-refractory patients, leading the hematology niche market.

Q

Up to now, 

d

Up to now, there are a

There are